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Abstract
Due to its small size and versatility, the biarsenical-tetracysteine system is an attractive way to label viral proteins for live cell
imaging. This study describes the genetic labeling of the human immunodeficiency virus type 1 (HIV-1) structural proteins
(matrix, capsid and nucleocapsid), enzymes (protease, reverse transcriptase, RNAse H and integrase) and envelope
glycoprotein 120 with a tetracysteine tag in the context of a full-length virus. We measure the impact of these modifications
on the natural virus infection and, most importantly, present the first infectious HIV-1 construct containing a fluorescently-
labeled nucleocapsid protein. Furthermore, due to the high background levels normally associated with the labeling of
tetracysteine-tagged proteins we have also optimized a metabolic labeling system that produces infectious virus containing
the natural envelope glycoproteins and specifically labeled tetracysteine-tagged proteins that can easily be detected after
virus infection of T-lymphocytes. This approach can be adapted to other viral systems for the visualization of the interplay
between virus and host cell during infection.
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Introduction
Fluorescent viral fusion proteins have been instrumental in the
visualization of the intracellular behavior of viruses during
infection [1–3]. However, the incorporation of these 27 kDa
fluorescent proteins (FPs) into most viral proteins has limited
application due to its potential impact on viral protein function
and infectivity [4–7]. This problem has been partially overcome
with the development of the biarsenical-tetracysteine labeling
system [8], in which the protein of interest is fused to a six to
twelve amino acids tetracysteine motif (TC tag), which is only 0.5–
1 kDa and therefore less likely to interfere with the structure or
biological activity of the protein. The TC tag can be labeled with
membrane-permeable biarsenical dyes such as FlAsH and ReAsH
[9,10].
The TC tag has been inserted at the carboxy-terminus of the
human immunodeficiency virus type 1 (HIV-1) matrix (MA)
[11,12], HIV-1 integrase (IN) [13] and vesicular stomatitis virus
(VSV) MA protein [5,14] without compromising virus infectivity.
However, insertion of the TC tag into the cyclophilin-binding
loop of HIV-1 capsid (CA) severely impaired infectivity to the
extent thatvirusinfectivity needed to be rescued by co-expression
of TC tagged and wild-type (wt) proteins [15]. Another recent
study has elegantly shown that the loop/linker regions, but not
the a-helix regions of influenza A virus non-structural protein 1,
can accommodate TC tags without affecting virus infectivity
[16].
Two major limitations of the biarsenical-tetracysteine system
are the high degree of background fluorescence [17,18], and the
fact that the target cysteines in the TC tag must be in their reduced
form prior to binding to the biarsenical dyes [12,19]. Therefore,
previous studies of TC tagged viruses have resorted to: (a) the use
of a higher contrast twelve amino acids TC motif [12], (b)
extracellular labeling of TC tagged proteins under acutely
reducing conditions [12,13] and/or (c) increasing the number of
available TC tagged proteins inside the target cell via pseudotyped
viruses to improve the signal to noise ratio [11–13,15]. In the case
of HIV-1, HIV-1 pseudotyped with VSV glycoprotein (VSV-G)
instead of its natural envelope (Env) glycoproteins is commonly
used to increase the number of HIV-1 proteins inside target cells.
However, VSV-G pseudotyping does not represent the natural
viral entry process for HIV-1. Furthermore, the extracellular
labeling of viruses with biarsenical dyes under highly reducing
conditions is not suitable for all virus systems [14].
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17016The aim of the present study was to specifically label all of the
structural proteins and enzymes of HIV-1 with a TC tag in the
context of a full-length virus without affecting virus infectivity. We
employed three different strategies in this study. Firstly, we
inserted a six amino acids TC tag upstream and/or downstream of
each of the protease cleavage sites in the Gag or Gag-Pol precursor
protein. This resulted in specific labeling of MA, CA, nucleocapsid
(NC), protease (PR), reverse transcriptase (RT), RNase-H (RN)
and IN. Secondly, we inserted the TC tag into two highly flexible
regions of the mature RT enzyme and the Env glycoprotein 120
(gp120). Thirdly, using a conditional complementation rescue
approach, we generated an HIV-1 construct containing 80% TC-
labeled NC proteins. We also show that virus production in the
presence of biarsenical dyes followed by the removal of unbound
dye is a highly specific method for the labeling of viral proteins
containing a TC tag.
Results
Generation of mutant viruses containing tetracysteine-
tagged proteins
The aim of this study was to specifically label all of the structural
proteins and enzymes of HIV-1 with a TC tag in the context of a
full-length virus without affecting virus infectivity. To this end, we
created several full-length HIV-1 constructs containing TC tagged
proteins (HIV
TC). To minimize the potential impediment on virus
infectivity, we used the six amino acids TC motif instead of the
higher contrast twelve amino acids TC motif [10].
In the first labeling strategy we inserted the TC tag within the N-
terminus or C-terminus of the major mature Gag and Pol proteins.
The natural proteolytic cleavage sites were preserved by duplicating
the first or last five amino acids of the viral protein coding sequences
of the corresponding mature proteins (Figure 1A and Table 1).
Using this strategy the following HIV
TC were generated: HIV
MA-C,
HIV
CA-N, HIV
CA-C, HIV
NC-N, HIV
NC-C, HIV
PR-C, HIV
RT-N,
HIV
RT-C, HIV
RN-N, HIV
RN-C and HIV
IN-N. The protein process-
ingprofilesof theseHIV
TC were very similar from HIV
wt with a few
exceptions. HIV
RT-N, HIV
RT-C, HIV
RN-N, HIV
RN-C and HIV
IN-N
have reduced levels or completely lack the p66-RT subunit
(Figure 1B). The MA protein in HIV
MA-C showed a slower
electrophoretic mobility, which is likely due to the additional six
amino acids TC tag, as described previously [11,12]. Similarly, the
CA protein in HIV
CA-N and HIV
CA-C also showed a slower ele-
ctrophoretic mobility and appeared as a double band in HIV
CA-N.
The appearance of the CA doublet may result from non-specific
protease cleavage at the N-terminus of CA in HIV
CA-N. To assess
theeffectofthesemodificationsonthe virallife-cycle,the replication
kinetics of HIV
MA-C, HIV
CA-N, HIV
CA-C, HIV
NC-N, HIV
NC-C,
HIV
PR-C, HIV
RT-N, HIV
RN-N, HIV
RN-C and HIV
IN-N were
assessed in peripheral blood mononuclear cells (PBMCs), which
are the natural target cells of HIV-1 (Figure 1C). HIV
MA-C
replication levels and kinetics were very similar to HIV
wt. HIV
NC-C
and HIV
PR-C were 54% and 50% less infectious than HIV
wt,
respectively. The replication kinetics of HIV
NC-N was delayed
(maximum RT activity at day 11). The remaining viruses were
between 79-91% less infectious than HIV
wt.
In the second labeling strategy, we introduced the TC tag into
flexible regions of the RT and Env in order to limit the structural
and functional interference with the protein. These flexible regions
were chosen based on the crystal structure and biochemical
properties of the mature proteins (Figure 1A inserts). The TC tag
was inserted into the RT ‘‘thumb’’ subdomain between b14 and
aH or between aI and aJ to generate the HIV
RTt1 and HIV
RTt2,
respectively. HIV
Env-V1 and HIV
Env-V2 contain a TC tag in the
variable loops of the V1 or V2 region of gp120, respectively. The
location of each TC tag is indicated in Table 1.
The capacity of HIV
TC to enter lymphoid cells was assessed by
measuring the cytosolic activity of viral-core-associated b-lacta-
mase [20]. All HIV
TC were able to enter lymphoid cells
(Figure 1D), and all viruses showed similar entry efficiency as
HIV
wt, with the exception of HIV
RT-N, HIV
Rt1, HIV
RN-C and
HIV
IN-N, which were approximately 50% less efficient. The
capacity of HIV
TC to infect the indicator cell line TZM-bl
(Figure 1E) clearly showed that HIV
MA-C replicates as efficiently as
HIV
wt, as reported previously [11,12]. The remaining viruses
showed different degrees of infectivity. HIV
NC-N, HIV
NC-C,
HIV
PR-C and HIV
Env-V1 were 66%, 65%, 63% and 54% less
infectious than HIV
wt, respectively. HIV
RT-N was 84% less
infectious than HIV
wt and the remaining viruses were approxi-
mately 95% less infectious than HIV
wt.
Infectivity rescue of mutant viruses containing
tetracysteine-tagged nucleocapsid proteins
Since the structural proteins of HIV-1 are more permissive to
the insertion of the TC tag we attempted to rescue the infectivity of
the HIV
CA-N, HIV
NC-N and HIV
NC-C. A commonly used
approach to rescue the infectivity of fluorescently-labeled viruses
is to generate mixed virus particles through the co-transfection of
virus producer cells with equal masses of plasmids encoding for
virus containing wt and virus containing fluorescently-labeled
proteins [4,15]. One major limitation of this approach is that it
results in a heterogeneous population of virus particles containing:
(a) only wt proteins, (b) only fluorescently-labeled proteins and (c) a
mixture of wt and fluorescently-labeled proteins. We have
therefore adapted our previously described conditional co-
transfection system [21] to produce fluorescently-labeled HIV-1
containing a known ratio of wt/TC tagged proteins. The
production of viral particles is limited to cells that simultaneously
express both wt and TC tagged proteins. This system takes
advantage of the fact that both Gag and Rev are required for the
formation of infectious viral particles.
Firstly, the HIV
CA-N, HIV
NC-N, HIV
NC-C were modified to
introduce an early termination codon and a frameshift into exon 2
of the Rev sequence (HIV
TC-DRev) that inactivates Rev function
and therefore prevents the nuclear export of the unspliced
and single spliced HIV-1 mRNA. Thus, cells expressing only
HIV
TC-DRev cannot generate virus particles. Secondly, we
generated a full-length HIV-1 construct containing modifications
at the -1 frameshift slippery sequence and the immediate
downstream RNA pseudoknot that regulates Gag-Pol expression
(non-frameshift HIV-1 or HIV
NFS). These codon modifications
altered the coding sequence in the gag reading frame without
affecting the protein sequence enabling the expression of Gag but
not Gag-Pol. As HIV
NFS lacks the capacity to produce HIV
enzymatic proteins, cells expressing only HIV
NFS are unable to
produce mature and infectious viral particles. The built-in
constrains of HIV
TC-DRev and HIV
NFS ensure that fluorescent
infectious HIV-1 can only be produced when both proviral DNA
constructs are simultaneously expressed in the same cell. These
HIV-1 constructs are depicted in Figure 2A.
As the natural ratio of Gag to Gag-Pol synthesis is 20:1, the two
plasmids were co-transfected at a ratio of 4 HIV
TC-DRev to 1
HIV
NFS or 8 HIV
TC-DRev to 1 HIV
NFS to generate a theoretical
ratio of Gag to Gag-Pol of 25:1 and 22.5:1, respectively. These co-
transfection ratios should also result in virus particles containing a
ratio of TC tagged to wt Gag proteins of 80:20 or 88.9:11.1,
respectively. Firstly, we compared the infectivity of these condition-
ally-produced fluorescent viruses with the original HIV
TC viruses
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NC-N-DRev/NFS(4:1) and HIV
NC-C-DRev/NFS(4:1)
generated by co-transfection at a 4:1 ratio showed an increase in
infectivity (50% and 33%, respectively) when compared with the
original HIV
NC-N and HIV
NC-C viruses. HIV
NC-N-DRev/NFS(8:1) and
HIV
NC-C-DRev/NFS(8:1) generated by co-transfection at a 8:1 ratio
showed a less pronounced increase in infectivity (25% and 5%,
respectively) when compared with the original HIV
NC-N and
HIV
NC-C viruses. The reduced capacity of HIV
NC-DRev/NFS(8:1) to
rescue HIV infectivity when compared with HIV
NC-DRev/NFS(4:1) is
most likely due to an increase in the ratio of TC tagged to wt Gag
incorporated into the viral particles. Secondly, we compared
the infectivity of these conditionally-produced fluorescent viruses
with HIV
wt. HIV
NC-N-DRev/NFS(4:1), HIV
NC-C-DRev/NFS(4:1),
HIV
NC-N-DRev/NFS(8:1) and HIV
NC-C-DRev/NFS(8:1) showed 72%,
59%, 47% and 31% infectivity when compared with HIV
wt,
respectively. In contrast, HIV
CA-N-DRev/NFS generated by co-
transfection of proviral DNA at a 4:1 or 8:1 ratios did not show
an increase in infectivity when compared with the original
HIV
CA-N. Our data shows that this conditional co-transfection
system can be used to rescue the infectivity of selected HIV
TC viruses.
Specific labeling of tetracysteine-tagged viral proteins
The high level of background associated with the labeling of
low-abundance TC tagged proteins has significantly limited its
applicability in many virus systems. VSV-G pseudotyped viruses
are often used to increase the signal to noise ratio. In order to
establish a protocol where fluorescently labeled viruses can infect
their natural target cells using native envelope glycoproteins, we
have optimized a metabolic labeling system where TC-labeled
viruses are produced in the presence of the biarsenical dye FlAsH.
The excess dye and non-specifically labeled cellular debris were
removed by sucrose density gradient centrifugation. A similar
approach has been used recently for the labeling of a recombinant
TC tagged-VSV [14], showing the general applicability and
generic nature of this labeling approach. HIV
MA-C was chosen
based on its wt level of infectivity. HIV
MA-C produced in the
presence of the FlAsH dye is referred to as HIV
MA-C-F. HIV
wt was
alsogeneratedinparallelinthepresenceoftheFlAsHdye(HIV
wt-F)
to evaluate the specificity of the labelingand the potential packaging
ofnon-specificallylabeled cellularproteins.HIV
wt-Fand HIV
MA-C-F
have indistinguishable levels of viral production (Figure 3A) and
infectivity of a T-lymphocytic cell line (Figure 3B). Furthermore,
HIV
MA-C-F also show comparable levels and kinetics of viral cDNA
synthesis to HIV
wt (Figure 3B), illustrating that HIV
MA-C-F closely
mimics the earlyeventsofHIV-1replication.Oursystemresultsina
highly specific FlAsH labeling of TC tagged proteins in HIV
MA-C-F
but not in HIV
wt. The specificity of the FlAsH labeling was further
confirmed by colocalization of HIV
MA-C-F signal and immunoflu-
orescent staining with anti-MA or anti-CA monoclonal antibodies
(Figure 3C–D). The same results were observed when using the
biarsenical dye ReAsH (data not shown). Labeling of HIV
NC-C and
HIV
NC-C-DRev/NFS(4:1) with this metabolic labeling system shows
that NC can also be visualized using the biarsenical-tetracysteine
system (Figure 3E). Furthermore, HIV
NC-C-DRev/NFS(4:1)-F showed
onlyaminordecreaseinfluorescenceintensitywhencomparedwith
the HIV
NC-C-F, which is probably due to the fact that
HIV
NC-C-DRev/NFS(4:1)-F contains only 80% of TC-labeled NC
proteins per virus particle in comparison with HIV
NC-C-F
(Figure 3F).
Discussion
The imaging of fluorescent-labeled viruses is limited to the
visualization of a small number of viral proteins that can be
fluorescently labeled without compromising virus infectivity. Due
to its small size and versatility, the biarsenical-tetracysteine system
Table 1. Overview of the modifications introduced in the
HIV-1 genome.
Construct Amino acid sequence
Last 5 amino acids – AG linker (Nae I restriction site) –
TC tag – Duplication of Last 5 amino acids
HIV
MA-C VSQNYAGCCRECCVSQNY
HIV
CA-C KARVLAGCCRECCKARVL
HIV
NC-C ERQANAGCCRECCERQAN
HIV
PR-C CTLNFAGCCPGCCCTLNF
HIV
RT-C GAETFAGCCPGCCGAETF
HIV
RN-C IRKVLAGCCPGCCIRKVL
Duplication of First 5 amino acids –TC tag – AG linker
(Nae I restriction site) – First 5 amino acids
HIV
CA-N PIVQNCCRECCAGPIVQN
HIV
NC-N IQKGNCCRECCAGIQKGN
HIV
RT-N PISPICCPGCCAGPISPI
HIV
RN-N YVDGACCPGCCAGYVDGA
HIV
IN-N FLDGICCPGCCAGFLDGI
a.a. sequence – TC tag – a.a. sequence
HIV
RTt1 PIVLPEKCCPGCCDSWTV
HIV
RTt2 KALTEVVCCPGCCPLTE
HIV
Env-V1 CTDLKNDTNTCCPGCCNSSSGRMIMEKGEIKN
HIV
Env-V2 SFNISTSIRDKVQKEYAFFYKLDIVPIDNCCPGCCTSYRLISC
doi:10.1371/journal.pone.0017016.t001
Figure 1. Genetic labeling of HIV-1 proteins and its impact on virus infectivity. (A) Diagram of the HIV-1 gag (red), pol (brown) and env
(blue) open reading frames and the positions where the tetracysteine (TC) tag motif was inserted. The majority of the TC motifs were inserted five
amino acids downstream (-N tags) or upstream (-C tags) of the protease cleavage site and the first or last five amino acids of the viral protein coding
sequence were repeated to prevent alterations in the minimal recognition site for the viral protease. The left insert shows the crystal structure of the
RT enzyme and the positions in the ‘‘thumb’’ region where the TC tag was inserted are shown in blue. The right insert shows the crystal structure of
the Env gp120 and the positions in the V1/V2 region where the TC tag was inserted are shown in blue. (B) Virion protein processing profiles of 293T
cell-derived HIV
MA-C, HIV
CA-N, HIV
CA-C, HIV
NC-N, HIV
NC-C, HIV
PR-C, HIV
RT-N, HIV
RT-C, HIV
RN-N, HIV
RN-C and HIV
IN-N (lanes 1-12, respectively). HIV-1 proteins
were detected by Western Blot using pooled HIV-positive patient sera. Data are representative of 2 independent experiments. (C) The infectivity of
HIV
MA-C, HIV
CA-N, HIV
CA-C, HIV
NC-N, HIV
NC-C, HIV
PR-C, HIV
RT-N, HIV
RN-N, HIV
RN-C and HIV
IN-N was assessed by comparing their replication kinetics in
peripheral blood mononuclear cells with HIV
wt. Samples were collected at 3, 7, 11 and 14 days post infection, and the levels of virus replication were
monitored using an in vitro reverse transcriptase assay that is specific for HIV-1 enzymatic activity. Data are representative of 2-3 independent donors.
Error bars represent technical replicates. (D) The capacity of several HIV
TC to enter target cells was assessed by measuring b-lactamase activity in MT-2
cells that have been infected with HIV
TC containing a b-lactamase-Vpr fusion protein. Error bars, s.d. are based on the averages of 2-3 independent
experiments. (E) The capacity of HIV
TC to infect target cells was assessed by measuring luciferase activity in the indicator TZM-bl cells that have been
infected with the indicated viruses. Error bars, s.d. are based on the averages of 2-3 independent experiments.
doi:10.1371/journal.pone.0017016.g001
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e17016is an attractive generic approach to fluorescently label viral
proteins. The TC tag has been successfully used to label the HIV-1
MA [11,12], HIV-1 IN [13] and VSV MA [5,14] proteins. This
study describes the labeling of HIV-1 structural, enzymatic and
envelope proteins with a TC tag in the context of a full-length
HIV-1 and its effect on virus infectivity.
The insertion of the TC tag in the V1 and V2 flexible loops of
the Env gp120 showed surprisingly different results. While the
insertion in the V2 loop completely abolished virus infectivity, the
insertion in the V1 loop was less detrimental to virus infectivity.
This suggests that flexibility is not the only requirement for the
insertion of the TC tag and that the V1 loop but not the V2 loop
of gp120 is a good candidate for the insertion of a TC tag.
Furthermore, due to the limited number of Env molecules in the
virion [22], the new generation of brighter biarsenical dyes such as
Alexa Fluor 568-FlAsH may be more suitable for the visualization
of TC tagged Env [23].
Insertion of the TC tag at the C-terminus of the PR did not
affect the proteolytic processing of HIV-1 proteins, indicating that
it can potentially be used for the visualization of the production,
assembly, budding and maturation of HIV-1. On the other hand,
insertion of the TC tag at the N- and C-terminus as well as in the
flexible ‘‘thumb’’ subdomain of the RT dramatically affected virus
production, entry and infectivity. This is not surprising due to the
fact that the RT undergoes highly precise and complex structural
rearrangements during reverse transcription that might be affected
by the smallest modifications [24,25]. A possible solution to this
problem may be long-term culture of the HIV
RT in lymphocytes
to introduce compensatory mutations and therefore restore virus
infectivity. Introduction of the TC tag at the N-terminus of the IN
abolished HIV-1 infectivity, which indicates that as described
previously [13], the C-terminus of IN is more permissive to the
introduction of the TC tag.
We confirm that the TC tag can be inserted at the C-terminus
of the MA protein without affecting virus infectivity [11,12].
Similarly to what has been described previously for the
cyclophilin-binding loop of CA [15], insertion of the TC tag at
both the N- and C-terminus of the CA protein completely
abolished virus infectivity, suggesting that the stability of the highly
ordered CA lattice might be compromised by the TC tag. The
most encouraging result from this analysis is that the insertion of
the TC tag at either the N- or C-terminus of the NC protein only
partially affected virus infectivity. Using a conditional co-
transfection system we were able to rescue the infectivity of both
the HIV
NC-N and HIV
NC-C to 72% and 59% of the HIV
wt
infectivity while retaining enough TC tagged NC proteins for
visualization by fluorescence microscopy. These are the first
infectious HIV-1 containing fluorescently-labeled NC proteins that
will allow the visualization of the intracellular trafficking of the
HIV-1 genome-NC complexes in live cells. Furthermore, the
approaches described in this study can be applied to other virus
systems. The genetic variances found within any group of viruses
Figure 2. Improve the infectivity of the gag-TC viruses. (A) Schematic representation of proviral DNA constructs used in the study. The
HIV
TC-DRev construct differs from HIV
TC by the introduction of an early termination codon and a frameshift into exon 2 of the Rev sequence, which was
removed to inactivate Rev function. This mutation also affects Env expression. HIV
NFS is a full-length HIV-1 construct containing codon modifications
in the -1 frameshift slippery sequences and the RNA pseudoknot in the gag reading frame to enable the expression of Gag but not Gag-Pol. (B) The
capacity of HIV
TC-DRev/NFS to infect target cells was assessed by measuring luciferase activity in the indicator TZM-bl cells that have been infected with
the indicated viruses. Error bars, s.d. are based on the averages of 3-5 independent experiments.
doi:10.1371/journal.pone.0017016.g002
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genome will be able to accommodate the six amino acids TC tag
without compromising virus infectivity.
Using HIV
MA as a model system, we have improved the
biarsenical-TC labeling system for the visualization of viral
proteins during the early events of a natural virus infection. This
generic protocol is built on three premises: firstly, the viral genome
must contain segments that are sufficiently flexible for the insertion
of a six amino acids TC tag without compromising the biological
function of the protein and the infectivity of the virus; secondly,
multiple copies of the TC tagged protein must be incorporated
into the virion during assembly; thirdly, any non-specifically
labeled cellular debris and non-incorporated free biarsenical dye
must be readily removed from the labeled viruses through virus
purification procedures.
Furthermore, it is imperative to generate a wild-type virus in
parallel with the TC tagged virus in the presence of the biarsenical
dye in order to evaluate the specificity of the labeling and the
potential packaging of non-specifically labeled cellular proteins. By
using a metabolic labeling approach that can easily be adapted to
other viruses, we have bypassed the requirement for high
concentrations of reducing agents during labeling. Using appro-
priate and specific virus purification procedures (such as sucrose
density gradient centrifugation), we have found that non-
specifically labeled cellular debris and excess dye can be efficiently
removed, which leads to a substantial decrease in background
fluorescence.
In conclusion, this study identifies novel tools for the imaging of
HIV-1 proteins during its natural infection process. Furthermore,
this study describes generic approaches to label viral proteins with
a TC tag without compromising virus infectivity as well as a
specific and generic method to improve the labeling of TC tagged
viral proteins with biarsenical dyes in the context of an infectious
virus.
Methods
Cells
293T cells were maintained in Dulbecco’s modified Eagle
medium/high modified (with 4500 mg/l dextrose and 4 mM L-
glutamine) medium (DMEM; Invitrogen, Mount Waverley,
Victoria, Australia), supplemented with 10% (vol/vol) heat-
inactivated cosmic calf serum (CCS; Hyclone, Tauranga, New
Zealand), 100 U/ml of penicillin and 100 mg/ml of streptomycin
(Invitrogen). MT-2 cells (obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH
from D. Richman) [26,27] were cultured in Rosewell Park
Memorial Institute (RPMI) 1640 medium (Invitrogen) supple-
mented with 10% vol/vol heat-inactivated fetal calf serum (FCS;
Invitrogen) and penicillin/streptomycin. TZM-bl cells (obtained
through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr.
Xiaoyun Wu and Tranzyme Inc.) are derived from the HeLa cell
line and stably express high levels of CD4, CXCR4, and CCR5 on
the cell surface and have integrated copies of the luciferase and b-
galactosidase genes under control of the HIV-1 promoter. TZM-bl
cells were cultured in DMEM supplemented with 10% CCS and
penicillin/streptomycin. Peripheral Blood Mononuclear Cells
(PBMCs) were isolated from buffy packs (supplied by the Red
Cross Blood Bank, Melbourne) using Ficoll-Hypaque density
gradient centrifugation (Amersham Pharmacia Biotech, Uppsala,
Sweden). PBMCs were then stimulated with 10 mg/ml phytohe-
magglutinin (PHA; Remel, Lenexa, KS, USA) for 3 days and
maintained in RPMI 1640 medium supplemented with 10% CCS,
2 mM L-glutamine (Invitrogen), 50 mg/ml gentamycin (Pfizer,
Bentley, WA, Australia) and 10 U/ml of human interleukin-2 (IL-
2; Roche, Mannheim, Germany).
Viruses
The pNL4-3 proviral DNA (NIH AIDS Research & Reference
Reagent Program, Dr. Malcolm Martin [28]) contains the NL4-3
infectious molecular clone of HIV-1. The HIV-1 constructs with a
tetracysteine (TC) tag were generated using stitch PCR mutagen-
esis on the full-length pDRNL. Sequence-specific primers were
used to introduce the TC motif at the sites indicated in Figure 1A
and Table 1. The region of interest was then amplified using HIV-
1 specific primers and subcloned back into the pDRNL backbone
using the appropriate restriction sites. The primers used in this
study are described in Table 2. In the HIV
MA-C, HIV
CA-N,
HIV
CA-C, HIV
NC-N, HIV
NC-C, HIV
PR-C, HIV
RT-N, HIV
RT-C,
HIV
RN-N, HIV
RN-C and HIV
IN-N constructs, the TC tag was
inserted five amino acids downstream and/or upstream of each of
the protease cleavage sites in the Gag or Gag-Pol precursor protein
and a Nae I restriction site was introduced downstream or
upstream of the TC tag to improve screening. In addition, the first
or last five amino acids of the viral protein coding sequence were
repeated downstream or upstream of the TC tag to maintain the
viral protease cleavage sites.
The HIV
TC-DRev plasmid differs from HIV
TC by the introduc-
tion of an early termination codon and a frameshift into exon 2 of
the Rev sequence, which inactivates Rev function. The Rev
inactivation mutation was achieved by incorporation of a early
Figure 3. Labeling of tetracysteine-tagged matrix proteins of an infectious HIV-1 does not impact on virus function. (A) Production of
HIV
wt and HIV
MA-C from 293Ts that have been untreated (no FlAsH) or incubated with 1 mM FlAsH-EDT2 (FlAsH). The level of virus production was
measured with an in vitro reverse transcriptase assay that is specific for HIV-1 enzymatic activity. Data are representative of 2 independent experiments.
Error bars represent technical replicates. (B) Quantitative PCR analysis of the kinetics of HIV-1 cDNA synthesis during an infection in MT-2 cells. Cells were
infected with HIV
wt or with HIV
wt and HIV
MA-C produced in the presence of 1 mMF l A s H - E D T 2 as described above (HIV
wt-F and HIV
MA-C-F). Cells were
harvestedattheindicatedtimepointspost-infectionandanalyzedbyquantitativePCRforbothearly([-]ssDNA)andlate(post secondstrandtransfer)HIV-
1 reverse transcription products. HIV-1 cDNA copies were normalized by the number of copies of the CCR5 gene in the host cells. Data are representative
of 2 independent experiments. (C-D) Specificity of the labeling of tetracysteine-tagged virus with biarsenical dyes. (C) HIV
MA-C-F and HIV
wt-F (cell-free virus)
were immunostained with HIV-1 p17-MA and p24-CA mAb followed by donkey anti-mouse Alexa Fluor 647. (D) MT-2 cells were fixed after 20 min of
synchronized infection with HIV
MA-C-F or HIV
wt-F and immunostained with HIV-1 p17-MA and p24-CA monoclonal antibodies followed by donkey anti-
mouse Alexa Fluor 647 secondary antibody. Nuclei were labeled with Hoechst. FlAsH is shown in green, Alexa Fluor 647 in red and nuclei in blue. The
provided images were derived from a volume compression of a z stack of 10-38 images taken at a 0.2-mm step size. Scale bar, 5 mm. Images are
representativeofmorethan3independentexperiments.(E)MT-2cellswereinfectedwithHIV
NC-CorHIV
NC-C-DRev/NFS(4:1)producedinthepresenceof1 mM
FlAsH-EDT2 as described above (HIV
NC-C-F or HIV
NC-C-DRev/NFS(4:1)-F, respectively). The infected cells were fixed after 4 h of synchronized infection, and the
nucleiwerelabeledwithHoechst.FlAsHisshowningreenandnucleiareshowninblue.Theprovidedimageswerederivedfromavolumecompressionof
a z stack of 26 images taken at a 0.5-mm step size. Scale bar, 5 mm. Images are representative of 2 independent experiments. (G) Quantification of the
relative intensity of FlAsH staining using softWoRx software (Applied Precision, Issaquah, WA) following infection with HIV
NC-C-F or HIV
NC-C-DRev/NFS(4:1)-F.
Eachsymbolrepresentsaseparatefieldfromthesameexperiment.Theblacklinesshowthemean.Dataarerepresentativeof2independentexperiments.
doi:10.1371/journal.pone.0017016.g003
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NFS plasmid was cons-
tructed by replacing the wt sequence with 59 CTTCCTC-
GGGAAG ATATGGCCATCACACAAAGGTAGACCT 39 be-
tween DNA nucleotides 4240-4266 employing the ApaI and BclI
sites of the HIV-1 molecular clone [29].
HIV-1 particles were produced by poly(ethylenimine) (PEI;
Polysciences Inc., Warrington, PA, USA) transfection of 293T cells
cultured in 10-cm plates with: 3.5 mg pDRNL or HIV
TC plasmids
to generate unlabeled viruses; 2.5 mg pDRNL or HIV
TC plasmids
and 1 mg pMM310 b-lactamase-Vpr plasmid (kindly donated by
Table 2. Primers used for site-directed mutagenesis.
Name Primers containing the tetracysteine motif (59 -.39)
HIV
MA-C FW gccggctgctgccgcgagtgctgcgtcagccaaaattaccctatagtgcagaacctccaggg
RW gtaattttggctgacgcagcactcgcggcagcagccggcgtaattttggctgacctggctg
HIV
CA-N FW cctatagtgcagaactgctgccgcgagtgctgcgccggccctatagtgcagaacctccaggg
RW gccggcgcagcactcgcggcagcagttctgcactatagggtaattttggctgacctggc
HIV
CA-C FW gccggctgctgccgcgagtgctgcaaagcaagagttttggctgaagcaatgagccaagtaac
RW caaaactcttgctttgcagcactcgcggcagcagccggccaaaactcttgctttatggccggg
HIV
NC-N FW atacagaaaggcaattgctgccgcgagtgctgcgccggcatacagaaaggcaattttaggaacc
RW gccggcgcagcactcgcggcagcaattgcctttctgtatcattatggtagctggatttgttacttg
HIV
NC-C FW gccggctgctgccgcgagtgctgcgagagacaggctaattttttagggaagatctggccttcc
RW attagcctgtctctcgcagcactcgcggcagcagccggcattagcctgtctctcagtacaatctttc
HIV
PR-C FW gccggctgctgcggcccatgctgctgcactttaaattttcccattagtcctattgagactg
RW aaaatttaaagtgcagcagcatgggccgcagcagccggcaaaatttaaagtgcagccaatctg
HIV
RT-N FW cccattagtcctatttgctgcggcccatgctgcgccggccccattagtcctattgagactg
RW gccggcgcagcatgggccgcagcaaataggactaatgggaaaatttaaagtgcagccaatctg
HIV
RT-C FW gccggctgctgcggcccatgctgcggagcagaaactttctatgtagatggggcagccaatagg
RW gaaagtttctgctccgcagcatgggccgcagcagccggcgaaagtttctgctcctattatggg
HIV
RTt1 FW tgctgccccgggtgctgcgacagctggactgtcaatgac
RW gcagcacccggggcagcacttttctggcagcactatagg
HIV
RTt2 FW tgctgccccgggtgctgcccactaacagaagaagcagagc
RW gcagcacccggggcagcatactacttctgttagtgctttgg
HIV
RN-N FW tatgtagatggggcatgctgcggcccatgctgcgccggctatgtagatggggcagccaatagg
RW gccggcgcagcatgggccgcagcatgccccatctacatagaaagtttctgctcctattatggg
HIV
RN-C FW gccggctgctgcggcccatgctgcatcaggaaagtactatttttagatggaatagataaggcc
RW tagtactttcctgatgcagcatgggccgcagcagccggctagtactttcctgattccagc
HIV
IN-N FW tttttagatggaatatgctgcggcccatgctgcgccggctttttagatggaatagataaggcc
RW gccggcgcagcatgggccgcagcatattccatctaaaaatagtactttcctgattccagc
HIV
Env-V1 FW tacctgctgtccaggatgttgcaatagtagtagcgggagaatg
RW tattgcaacatcctggacagcaggtattagtatcattcttcaaatc
HIV
Env-V2 FW taattgctgtccaggatgttgcaccagctataggttgataagttg
RW tggtgcaacatcctggacagcaattatctattggtactatatcaag
Name HIV-1 NL4.3 specific primers (59 -.39)
HIV 631 FW tggcgcccgaacagggac
NL 3700 RW ggataggtggattatgtgtcatccatcc
NL 3538 FW cacagtggggggacatcaagcagcca
NL 4266 RW tggccttcccttgtgggaagg
NL 1878 FW ctgaagcaatgagccaagtaac
NL 2500 RW ttgacaggtgtaggtcctac
NL 4373 FW gacaacaactccctctcagaagcaggagccgata
NL 5176 RW catgctacactggaatattgctgg
HIV Age I FW taaggcaattatgtaaacttcttagg
HIV Not I RW catattgtgagtctgtcactatg
HIV Not I FW gaagttatggtaccagttagaga
HIV Pflm I RW ggtatttcttatagcagattctg
doi:10.1371/journal.pone.0017016.t002
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Vpr-labeled viruses; 5 mg HIV
TC-DRev plasmids and 2.5, 1.25 or
0.63 mg HIV
NFS plasmid to generate HIV
TC-DRev/NFS viruses.
Forty hours post-transfection supernatant from 293T cells was
harvested, purified, filtered and virus production quantified by
micro-reverse transcriptase (RT) assay. Briefly, a sample of the
culture supernatant was mixed with an equal volume of 0.3% vol/
vol Nonidet P-40, followed by addition of RT reaction cocktail
containing the template primer poly(rA)-(dT)15 (GE Healthcare,
Rydalmere, Australia) and [a
33P]-dTTP (PerkinElmer, Waltham,
MA, USA). Following incubation for 3 h at 37uC, RT activity was
determined by the level of [a
33P]-dTTP using a TopCount
NXT
TM Microplate Scintillation and Luminescence Counter
(Perkin Elmer, Glen Waverley, Australia). Viral particles were
concentrated by ultracentrifugation through a 20% sucrose
cushion at 100,000 g for 1 h at 4uC using an L-90 ultracentrifuge
(SW 41 rotor; Beckman, Fullerton, CA, USA) and virus pellets
were resuspended in 1x phosphate buffered saline (PBS; Invitro-
gen) and quantified using a HIV-1 antigen (p24 CA) Micro
enzyme-linked immunosorbent assay (ELISA) (Vironostika: Bio-
merieux, Boxtel, The Netherlands).
Metabolic labeling of virus with biarsenical dyes
Eight hours after transfection the virus producer cells were
incubated with 1 mM FlAsH-EDT2 (Invitrogen) premixed with
12.5 mM 1,2-Ethanedithiol (EDT; Sigma-Aldrich, Sydney, Aus-
tralia) and virus production was allowed to proceed for 40 h. Viral
particles were isolated, purified, filtrated and concentrated as
described above. Non-incorporated free biarsenical dye was
removed from the virions by sucrose density gradient centrifuga-
tion. Briefly, biarsenical dye-labeled viral particles were layered on
top of sucrose density gradients prepared in PBS in 2.5%
increments ranging from 30 to 55% sucrose and centrifuged for
16 h at 100,000 6 g (SW41 rotor; L-90 Ultracentrifuge).
Afterwards, gradient fractions were collected, a micro-RT assay
was used to determine the location of the virion particles in the
gradient fractions, the virus-containing fractions were pooled
together and the virus was re-concentrated by ultracentrifugation
and quantified by (p24-CA) Micro ELISA.
Protein isolation and western blot analysis
Intracellular viral protein was isolated from transfected 293T
cells by washing cells twice with PBS then lysing with Tris-buffered
saline (TBS) lysis buffer containing 1% Nonidet P-40, 20 mM
phenylmethylsulfonylfluoride (PMSF), 1 mM pepstatin and 1 mM
leupeptin. Cell lysates were freeze-thawed in liquid nitrogen and
then clarified by centrifugation. Concentrated virions were
obtained by ultracentrifugation as described above and lysed with
TBS lysis buffer. Western blot analysis was carried out using
pooled sera from HIV-1 infected patients to detect total HIV-1
proteins.
b-lactamase assay
One million MT-2 cells were infected with HIV
wt/BlaM-Vpr and
HIV
MA/BlaM-Vpr viruses (normalized to 100 ng of p24) for 1 h at
37uC, 5% CO2, washed and loaded with the b-lactamase substrate
CCF2-AM (GeneBLAzer in vivo Detection Kit, Invitrogen) for
7 h at RT. Afterwards, the cells were washed and fixed with 4%
formaldehyde (Polysciences, Warrington, PA) in 0.1 M Pipes
buffer, pH 6.8. The extent of virus-cell fusion was determined
from the ratio of blue (440–480 nm) and green (518–538 nm)
emission of CCF2-AM upon exciting the cells at 405–415 nm
using a Fluorescence-Activated Cell Sorter (FACScan
TM Flow
Cytometer; BD, North Ryde, Australia) and analyzed using
FlowJo software (FlowJo, Ashland, OR).
Luciferase assay
TZM-bl cells were placed in 96-well plates at a concentration of
2E+04 cells/well and incubated for 24 h at 37uC, 5% CO2.
Afterwards the culture medium was replaced by culture medium
containing 10 mg/ml diethylaminoethyl-dextran (DEAE-dextran)
and the cells infected with 2-fold serial dilutions of pDRNL or
HIV
TC viruses. After 48 h incubation at 37uC, 5% CO2 the
medium was aspirated and 35 ml of cell culture lysis reagent
(Promega, Wisconsin, USA) was added to each well. 5 ml of each
sample was mixed with 25 ml of Luciferase Assay Substrate
(Promega) and luminescence was measured using the FLUOstar
OPTIMA multi-detector reader (BMG Labtech).
Replication kinetics in PBMCs
Sample virus stocks with equivalent levels of RT activity, as
determined by a micro-RT assay, were added to 1610
5 PBMCs in
96-well tissue culture plates. Eight 10-fold serial dilutions of each
virus were tested in triplicate. Supernatants were collected on days
3, 7, 10 and 14 post-infection and virus infectivity was measured
by monitoring the production of viral RT activity by using a
micro-RT assay.
Infection of lymphoid cells
Synchronized infections were performed as described previously
[30]. MT-2 cells were spinoculated with virus at 17uC for 2 h at
1,200 6 g. Afterwards, the cells were washed twice with PBS to
remove unbound virus and incubated with warm media at 37uC,
5% CO2 for 20 min to initiate infection. Afterwards, the cells were
washed, treated with 2 mg/ml of protease from Streptomyces griseus
(pronase E; Sigma) for 10 min on ice and washed extensively with
PBS containing 20% FCS. The cells were then fixed with 4%
formaldehyde in 0.1 M Pipes buffer, pH 6.8 or incubated at 37uC,
5% CO2 for 4 h before fixation and cytospined into glass slides.
Cell-free viruses (same batch as used for the infection of lymphoid
cells) were fixed with 4% formaldehyde (Polysciences) in 0.1 M
Pipes buffer, pH 6.8, spread on glass slides, incubated at 4uC for
16 h and washed twice with PBS.
Immunofluorescence staining
Cells and virus were permeabilized and stained with mouse anti-
matrix (SVM-33) antibody (MH-SVM33C9, ATCC, Manassas,
VA (Akzo Nobel N.V.) and/or mouse anti-capsid (AG3.0)
antibody (NIH AIDS Research & Reference Reagent Program,
Dr. Jonathan Allan) [31] and goat Cy5-conjugated anti-mouse
secondary antibody (Jackson ImmunoResearch, USA). After
staining, the cells were counterstained with Hoechst 33258
(Invitrogen). Samples were mounted in Fluoromount-G (Electron
Microscopy Sciences, Hatfield, PA) and images were captured in a
z series on a charge-coupled device (CCD) camera (CoolSnap
HQ; Photometrics, Tucson, AZ) through a 100x 1.4 numerical
aperture (NA) oil immersion lens on a DeltaVision microscope
(Applied Precision, Issaquah, WA) and deconvolved using soft-
WoRx deconvolution software (Applied Precision).
Quantitative PCR for HIV-1 reverse transcription products
Quantification of HIV-1 reverse transcription products and
standardization of cell numbers was performed using quantitative
PCR. Concentrated virus stocks were treated with 90 U/ml of
Benzonase (Sigma) for 15 min at 37uC before infection to remove
any contaminating plasmid DNA from the transfection procedure.
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efficient removal of plasmid DNA for each sample. MT-2 cells
were infected with equivalent amounts of virus as determined by a
HIV-1 antigen (p24-CA) Micro ELISA by spinoculation at 17uC
for 2 h at 1,2006g [30]. Cells were then washed with warm PBS
and then culture in fresh medium at 37uC. Cells were harvested at
various time points post-infection and lysed in PCR lysis buffer
containing 10 mM Tris [pH 8.0], 50 mM KCl with 0.5% vol/vol
Triton-X100, 0.5% vol/vol NP-40 and 75 mg/ml proteinase K
(Roche). Samples were incubated at 56uC for 2 h before the
proteinase K was inactivated at 95uC for 10 min, samples were
then stored at –20uC. Quantitative PCR was performed on an
MX3000P QPCR machine (Stratagene). Each PCR reaction
contained 1x Brilliant II SYBR Green Master mix (Stratagene),
400 nM each primer and 5 ml of cell lysates (1:10 dilution) in a
15 ml reaction volume. The HIV-1 specific primers M667 (59-
GGCTAACTAGGGAACCCACTG-39) and AA55 (59-CTGC-
TAGAGATTTTCCACACTGAC-39) were used to detect early
HIV-1 cDNA ([-]strong-stop DNA). The HIV-1 specific primers
M667 (59-GGCTAACTAGGGAACCCACTG-39) and M661 (59-
CCTGCGTCGAGAGATCTCCTCTGG-39) were used to detect
late HIV-1 reverse transcription products (post 2nd strand
transfer). HIV-1 PCR conditions were an initial denaturation at
95uC for 15 min followed by 40 rounds of cycling at 95uC for 10 s,
then 60uC for 30 s. Cell numbers were standardized for the
human CCR5 gene using the primers LK46 (sense; 59-
GCTGTGTTTGCGTCTCTCCCAGGA-39) and LK47 (anti-
sense; 59-CTCACAGCCCTGTGCCTCTTCTTC-39). CCR5
PCR conditions were an initial denaturation at 95uC for 10 min
followed by 40 rounds of cycling at 95uC for 20 s, 58uC for 40 s
and 72uC for 40 s.
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